Detalhe da pesquisa
1.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
J Am Acad Dermatol
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556093
2.
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
J Am Acad Dermatol
; 88(5): 1008-1016, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574595
3.
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
J Am Acad Dermatol
; 87(4): 815-824, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35863467
4.
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
J Am Acad Dermatol
; 85(4): 863-872, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33957195
5.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Qual Life Res
; 29(2): 369-380, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31655974
6.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
N Engl J Med
; 373(14): 1318-28, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26422722
7.
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Acta Derm Venereol
; 96(4): 514-20, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26837052
8.
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
J Am Acad Dermatol
; 73(1): 27-36.e1, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25982539
9.
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
Am J Clin Dermatol
; 24(2): 305-313, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370336
10.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
JAMA Dermatol
; 159(6): 613-620, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133856
11.
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
J Am Acad Dermatol
; 66(2): e33-45, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20850895
12.
An Open Letter to Health Canada.
J Cutan Med Surg
; 21(3): 195-196, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28903599
13.
Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.
Eur J Dermatol
; 21(1): 89-94, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21227890
14.
Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.
Dermatol Ther
; 21 Suppl 3: S6-14, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19076630
15.
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
N Engl J Med
; 349(21): 2004-13, 2003 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-14627785
16.
Relapse, rebound, and psoriasis adverse events: an advisory group report.
J Am Acad Dermatol
; 54(4 Suppl 1): S171-81, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16488339
17.
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
J Am Acad Dermatol
; 55(4): 598-606, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17010738
18.
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
BMC Dermatol
; 6: 9, 2006 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-17067371
19.
A fixed-dose combination of adapalene 0.1%-BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne.
J Dermatolog Treat
; 23(1): 26-34, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22103674
20.
Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.
Int J Dermatol
; 49(7): 818-28, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20618506